Disrupting the future of food with gene-editing

Federico Tripodi, MBA’08, is CEO of Calyxt, a gene-editing technology company focused on the food and agriculture industries, that celebrated its initial public offering on The Nasdaq Stock Market June 20, 2017.

Tripodi started his career in his native Argentina in 1998 in the research field of biotechnology traits and chemistry formulations; he moved to Saint Louis in 2001. He spent nearly two-decades in the ag biotech and seed industry with Monsanto. Calyxt is based in Minneapolis-St. Paul, MN, and is a wholly owned subsidiary of Paris-based Cellectis.

“As more and more food companies are looking for specialty ingredients that can help them to satisfy customers’ evolving needs and desire to lead healthier lifestyles, Calyxt is perfectly positioned to be an industry leader with the emergence of gene editing as a truly game-changing technology in the food space,” said Federico Tripodi, CEO, Calyxt. “Coupled with our innovative commercial strategy, this will allow Calyxt to meet the needs of today’s consumer preferences – all of the while helping to shape the landscape for the future of food as we know it.”

“Calyxt believes that the precision, specificity, cost-effectiveness and development speed of the company’s gene editing technologies will enable it to provide meaningful disruption to the food and agriculture industries. We are proud to welcome Calyxt to the Nasdaq family of innovators,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.

Source: GLOBE NEWSWIRE

Images: NASDAQ, Inc.